GEN Exclusives

More »

GEN News Highlights

More »
Nov 25, 2008

Abraxis BioScience to Reacquire U.S. Rights to Abraxane from AstraZeneca

  • Abraxis BioScience is seeking to re-acquire the exclusive rights to market Abraxane® (paclitaxel protein-bound particles for injectable suspension) in the U.S. from AstraZeneca.

    In April of 2006, AstraZeneca inked a five and a half year copromotion agreement with Abraxis, under which Abraxis received an upfront fee of $200 million.

    “We believe the time has come to further build our commercialization platform for Abraxane in the U.S.,” said Patrick Soon-Shiong, M.D., chairman and CEO of Abraxis BioScience. “We have gained much in our collaboration with AstraZeneca and they have done a commendable job in building market share. ”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?